Vanda Pharmaceuticals (VNDA) Short-term Investments (2010 - 2026)

Vanda Pharmaceuticals has disclosed Short-term Investments across 17 years of filings, most recently posting $148.3 million for Q1 2026.

• Short-term Investments for Q1 2026 came in at $148.3 million, down 35.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $148.3 million (down 35.28% YoY), and the FY2025 annual result was $179.0 million, down 34.27% from the prior year.
• Short-term Investments came in at $148.3 million for Q1 2026 at Vanda Pharmaceuticals, down from $179.0 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $405.4 million in Q3 2022 to a low of $147.3 million in Q1 2023.
• The 5-year median for Short-term Investments is $272.3 million (2024), against an average of $274.1 million.
• Across the five-year window, Short-term Investments slumped 59.99% in 2023 and jumped 82.58% in 2024, its largest moves.
• Vanda Pharmaceuticals' Short-term Investments stood at $331.8 million in 2022, then retreated by 23.92% to $252.4 million in 2023, then increased by 7.88% to $272.3 million in 2024, then sank by 34.27% to $179.0 million in 2025, then slipped by 17.16% to $148.3 million in 2026.
• The last three Short-term Investments figures came in at $148.3 million (Q1 2026), $179.0 million (Q4 2025), and $223.7 million (Q3 2025), per Business Quant data.